Sie sind hier: Skip Navigation LinksKlinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie

AG Myeloid Research

Acute myeloid leukemia (AML) and myelodysplastic syndroms (MDS) present highly heterogeneous regarding their clinical course as well as the genetic aberrations responsible to initiate the disease. As new therapeutic options are becoming available, it is increasingly important to define and characterize each patient's disease precisely in order to then select the best possible treatment. While the established techniques of microscopy, FACS analysis of cell surface markers and cytogenetics continue to play an essential role in this respect, more recent technological advances are allowing us to look even deeper into the genetic material and to uncover new information relevant to diagnosis and therapy. We are developing and applying these techniques to provide a high-resolution profile of the disease before treatment, but also enable us to monitor the response very closely during and after treatment.
Within our translational research, we try to define new clinical, and genetic factors that help to predict treatment outcomes in AML patients. Additionally, we address new ways that help us to better quantify response to treatment at high sensitivity (so called measurable residual disease, MRD). We integrate expression of AML-associated genes as well as distinct gene mutations into MRD analysis and try to better understand which marker will allow the best outcome prediction in which AML patient at which time point.

Furthermore, within our basic research, we try to dissect pathways that help us to better understand how myeloid neoplasms are driven and how we can exploit this knowledge to develop new treatment strategies or disease monitoring for these patients. We aim to exploit translational loops – starting from the identification of biological characteristics of the diseases, understanding the involved avenues of pathology, and reintegrating this gained knowledge into the clinic.

Our group was founded in 2012 by and around Dr. Sebastian Schwind after he returned from his post-doc research fellowship at the Ohio State University. We are a young and creative team that always warmly welcomes new members interested in myeloid research.

For further information about us, our work and contact information, please see our Web page (verlinkt auf https://ag-schwind.jimdosite.com )

Group Leaders

​PD Dr. med. Sebastian Schwind; MD 
PD Dr. med. Madlen Jentzsch, MD

Current Group members

Dr. med. Dominic Brauer, MD
Donata Backhaus, MD                       Jule Ußmann, MD                                Lara A. Bischof (MD student)       
Lisa Herrmann (MD student)

Current Funders

Zusammen gegen den Krebs e.V.             Werner Jackstädt Stiftung       
Deutsche Gesellschaft für Innere Medizin


 

Selected Publications

 

Biological and Clinical Implications of SRSF2 Mutations in Transplanted Acute Myeloid Leukemia Patients.

Grimm J, Jentzsch M, Bill M, Backhaus D, Brauer D, Küpper J, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S.

Am J Hematol. 2021; 96(10):1287-1294.

 

Measurable Residual Disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.

Jentzsch M, Grimm J, Bill M, Küpper J, Backhaus D, Brauer D, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S.

Bone Marrow Transplant. 2021 Jul 15. doi: 10.1038/s41409-021-01407-6. [Online ahead of print]

 

Clinical Value of the Measurable Residual Disease Status within the ELN Risk Groups in AML Patients undergoing Allogeneic Stem Cell Transplantation.

Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S.

Am J Hematol. 2021;96(7): E237-E239.

 

Clinical relevance of morphologic remission and MRD status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.

Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, Goldmann K, Niederwieser D, Platzbecker U, Schwind S.

Blood Cancer J. 2021; 11:80.

 

Nutritional status at diagnosis and pre-transplant weight loss impact outcomes of acute myeloid leukemia patients following allogeneic stem cell transplantation.

Brauer D, Backhaus D, Pointner R, Vucinic V, Niederwieser D, Platzbecker U, Schwind S, Jentzsch M.

Hemasphere. 2021; 5(3): e532.


High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population.

Jentzsch M, Bill M, Grimm J, Schulz J, Schuhmann L, Brauer D, Goldmann K, Wilke F, Franke GN, Behre G, Pönisch W, Vucinic V, Niederwieser D, Platzbecker U, Schwind S.

Haematologica. 2020 Jan 9;105(10):229260.

 

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.

Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S.

Bone Marrow Transplant. 2021 Apr;56(4):936-945.

 

Prognostic Impact of the ELN 2017 Risk Classification in AML Patients Receiving Allogeneic Transplantation.

Grimm J, Jentzsch M, Bill M, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S.

Blood Adv. 2020. Aug 25;4(16):3864–3874.

 

Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.

Grimm J, Bill M, Jentzsch M, Beinicke S, Häntschel J, Goldmann K, Schulz J, Cross M, Franke GN, Behre G, Vucinic V, Pönisch W, Lange T, Niederwieser D, Schwind S.

Bone Marrow Transplant. 2019 Aug;54(8):1189-1197.

 
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
                                                                                                                        Walker CJ, Oakes CC, Genutis LK, Giacopelli B, Liyanarachchi S, Nicolet D, Eisfeld AK, Scholz M, Brock P, Kohlschmidt J, Mrózek K, Bill M, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Niederwieser DW, Stone RM, Byrd JC, Schwind S, de la Chapelle A, Bloomfield CD.

Leukemia. 2019 Mar;33(3):771-775. 



 

Liebigstr. 20 (Haus 4) und 22 (Haus 7), Johannisallee 32A (Haus 9)
04103 Leipzig
Telefon (Sekretariat):
0341 - 97 13050
Ambulanz (Haus 9):
0341 - 97 13081
Fax:
0341 - 97 13059
Map